Evidence map›Paper›PMID 28853228›Full record

Trial reportJournal of diabetes investigation2018

Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients.

Akira Kurozumi, Yosuke Okada, Tadashi Arao, Takuya Kobayashi, Daisaku Masuda, Shizuya Yamashita, Yoshiya Tanaka

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of diabetes investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Akira KurozumiFirst Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.ORCID http://orcid.org/0000-0003-1768-3752
Yosuke OkadaFirst Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
Tadashi AraoFirst Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
Takuya KobayashiDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
Daisaku MasudaDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
Shizuya YamashitaDepartment of Community Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
Yoshiya TanakaFirst Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.
University of Occupational and Environmental Health Japan · JPThe University of Osaka · JPOsaka City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAnagliptin (ANA) improves dyslipidemia in addition to blood glucose levels. However, there are no comparative studies on the effects of ANA and other dipeptidyl peptidase-4 inhibitors on serum lipid profile. We compared the effects of ANA on serum lipid profile with those of alogliptin (ALO) in type 2 diabetes mellitus outpatients. MATERIALS AND

methodsThe study participants were 87 type 2 diabetes mellitus patients who had been treated with dipeptidyl peptidase-4 inhibitors for ≥8 weeks and had a low-density lipoprotein cholesterol (LDL-C) level of ≥120 mg/dL. Participants were switched to either 200 mg/day ANA or 25 mg/day ALO for 24 weeks.

resultsThere was no significant difference in percentage change in LDL-C level at 24 weeks between the ANA and ALO groups. Treatment with ANA for 12 weeks significantly decreased LDL-C levels, one of the secondary end-points. Treatment with ANA for 24 weeks significantly improved apolipoprotein B-100 levels, and the percentage change in LDL-C levels at 24 weeks correlated significantly with the percentage change in apolipoprotein B-100 levels in the ANA group.

conclusionsThe LDL-C-lowering effects of ANA and ALO at 24 weeks were almost similar in patients with type 2 diabetes mellitus. However, the results showed a tendency for a decrease in LDL-C level at 24 weeks in the ANA group, and that such improvement was mediated, at least in part, through the suppression of apolipoprotein B-100 synthesis.

Indexed as

AgedApolipoprotein B-100Blood GlucoseCholesterol, LDLDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsFemaleHumansHypoglycemic AgentsLipid MetabolismLipidsMalePiperidinesPyrimidinesTreatment OutcomeUracilalogliptinanagliptinApolipoprotein B-100Blood GlucoseCholesterol, LDLDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsLipidsPiperidinesPyrimidinesUracilApolipoprotein B-100Dipeptidyl peptidase 4 inhibitorType 2 diabetes mellitus

Identifiers

PMID28853228
PMCPMC5835469
OpenAlexW2751043776

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.